Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Are There Behavioural Rebound Effects If Cannabis for Dementia Is Stopped? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

As medical cannabis becomes more widely discussed in dementia care, families often ask what happens if someone stops taking it. Could stopping cannabis suddenly make behaviour or anxiety worse? Current research and clinical reviews suggest that rebound effects are possible, but usually mild and temporary when cannabis has been used under supervision. 

Can medical cannabis be accessed legally for women’s health?

What The Research Suggests 

Evidence from studies on older adults using cannabis for conditions such as chronic pain, anxiety, or sleep problems indicates that most people do not experience significant behavioural worsening after stopping medically prescribed cannabis. A 2025 University of California study on adults aged 65 and over found that withdrawal symptoms were uncommon and typically mild, such as irritability or restlessness, when use was short-term and low-dose (PubMed Central, 2025). 

However, people who used cannabis frequently or with high-THC content for months or years were more likely to experience short-term agitation, low mood, and disturbed sleep after discontinuation. These symptoms were usually transient, resolving within one to two weeks, and did not lead to lasting behavioural decline. 

Dementia-Specific Observations 

There are currently no NICE-approved cannabis-based treatments for dementia, and research into withdrawal in this population remains limited. According to the Alzheimer’s Society, there is no evidence that stopping medically supervised cannabis leads to worsening confusion or agitation. 

That said, if a person with dementia has been using cannabis products containing THC, sudden discontinuation may temporarily unmask underlying agitation, anxiety, or sleep disruption that the medication was helping to manage. This is sometimes mistaken for “rebound” when in fact it reflects a return of baseline symptoms once the drug’s effects wear off. 

NHS And NICE Advice 

NHS England notes that THC-containing products can cause drowsiness, confusion, and imbalance in older adults, and therefore any change in dosing should be done gradually and under medical supervision (NHS England, 2023). NICE guidance on dementia (NG97) and cannabis-based products (NG144) does not recommend cannabinoids for behavioural or cognitive symptoms, reinforcing that these medicines remain off-label for dementia (NICE, 2023). 

Clinical Bottom Line 

  • No strong evidence supports severe rebound symptoms after stopping medical cannabis in dementia. 
  • Temporary agitation, anxiety, or sleep changes may occur, especially with abrupt withdrawal of THC-heavy products. 
  • Gradual dose reduction under supervision helps prevent discomfort. 
  • Always consult a specialist before starting or stopping any cannabis-based treatment. 

Educational Context: AlleviMed 

AlleviMed provides educational information about how medical cannabis eligibility is assessed within UK regulations. Dementia is not currently an approved indication, but AlleviMed helps patients understand how clinical decisions around withdrawal, tapering, and monitoring are made in specialist care. 

Takeaway 

Stopping cannabis in dementia does not appear to cause major behavioural rebound, though mild irritability or sleep disruption can occur, especially if THC use has been long-term. Any dose changes should always be managed gradually and with clinical support. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories